MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Drug compound leads to death of ovarian cancer cells

Back to overy Blogs list Cancer blog  


Subscribe To Overy RSS Feed  RSS content feed What is RSS feed?

Drug compound leads to death of ovarian cancer cells




In a discovery that may be useful for maintaining remission in chemo-resistant ovary cancer, Yale researchers report that pre-clinical studies have shown the drug compound NV-128 can induce the death of ovary cancer cells by halting the activation of a protein pathway called mTOR.

Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine, and associate research scientist Ayesha Alvero, M.D. presented the data April 15 during an oral presentation at the annual meeting of the American Association for Cancer Research.



Drug compound leads to death of ovarian cancer cells

In cancer cells, mTOR signals enhance tumor growth and may be linked to resistance to conventional therapies. Inhibition of mTOR could shut down a number of of these survival pathways, including proteins that protect the mitochondria of cancer cells.

NV-128, developed by Novogen Limited, holds promise as a more targeted treatment for ovary cancer because it works differently from traditional therapies that are dependent on enzymes known as caspases to trigger cell death. Therapies using caspases to kill cancer cells can be ineffective in chemo-resistant cancer cells due to mutations that short-circuit signals that trigger cancer cell death.

We consider that the capacity of NV-128 to trigger caspase-independent cell death, in otherwise chemoresistant ovary cancer cells, opens new possibilities for the use of NV-128 as a potential addition to conventional chemotherapy targeting ovary cancer cells, said Mor.

In the context of developing therapies for late stage ovary cancer, Mor said, the finding may be a key step to the development of alternative targeted treatment for patients with cancer recurrence.


Posted by: Emily    Source




Did you know?
In a discovery that may be useful for maintaining remission in chemo-resistant ovary cancer, Yale researchers report that pre-clinical studies have shown the drug compound NV-128 can induce the death of ovary cancer cells by halting the activation of a protein pathway called mTOR.

Medicineworld.org: Drug compound leads to death of ovarian cancer cells

Ectopic pregnancy| Hyperemesis gravidarum vomiting of pregnancy| Obgyn| Menopause symptoms| Pre eclampsia| Seizures in pregnancy| Spontaneous abortion miscarriage| Symptoms of pregnancy| Ovariancancer| Ovarian cancer statistics| Risk factors for ovarian cancer| Role of radiation therapy in the treatment of ovarian cancer| Role of screening in ovarian cancer| Staging of ovarian cancer| Symptoms of ovarian cancer| Treatment of advanced stage ovarian cancer| Treatment of early stage ovarian cancer| Treatment of ovarian cancer| Treatment of recurrent ovarian cancer| What causes ovarian cancer| Who is more prone to ovarian cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.